Loren Michel
Overview
Explore the profile of Loren Michel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1028
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michel L, Jimeno A, Sukari A, Beck J, Chiu J, Ahern E, et al.
Clin Cancer Res
. 2024 Dec;
31(5):832-838.
PMID: 39665770
Purpose: Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and a PD-1 inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly...
2.
Han J, Zakeri K, Michel L, Sherman E, Lee N
Head Neck
. 2023 Oct;
46(1):230-231.
PMID: 37881148
No abstract available.
3.
Kuan E, Wang E, Adappa N, Beswick D, London Jr N, Su S, et al.
Int Forum Allergy Rhinol
. 2023 Sep;
14(2):149-608.
PMID: 37658764
Background: Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus...
4.
Han J, Zakeri K, Raab G, Hesse J, Shamseddine A, Chen L, et al.
Head Neck
. 2023 Jul;
45(9):2207-2216.
PMID: 37439286
Background: We report the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel. Materials And Methods: We included consecutive HNSCC patients treated from 2013 to...
5.
Kang J, Tchekmedyian V, Mohammed N, Rybkin A, Kitpanit S, Fan M, et al.
Int J Cancer
. 2021 Feb;
149(1):139-148.
PMID: 33586179
High-dose (HD) cisplatin remains the standard of care with chemoradiation for locally advanced oropharyngeal cancer (OPC). Cooperative group trials mandate bolus-HD (100 mg/m × 1 day, every 3 weeks) cisplatin...
6.
Kitpanit S, Lee A, Pitter K, Fan D, Chow J, Neal B, et al.
Int J Part Ther
. 2020 Jun;
6(4):17-28.
PMID: 32582816
Purpose: To demonstrate temporal lobe necrosis (TLN) rate and clinical/dose-volume factors associated with TLN in radiation-naïve patients with head and neck cancer treated with proton therapy where the field of...
7.
Fan M, Kang J, Lee A, Fan D, Wang H, Kitpanit S, et al.
Cancer
. 2020 Feb;
126(9):1905-1916.
PMID: 32097507
Background: Proton therapy (PT) improves outcomes in patients with nasal cavity (NC) and paranasal sinus (PNS) cancers. Herein, the authors have reported to their knowledge the largest series to date...
8.
Lee A, Kang J, Yu Y, McBride S, Riaz N, Cohen M, et al.
Int J Part Ther
. 2019 Nov;
5(4):1-10.
PMID: 31773036
Purpose: The purpose of this study was to analyze national trends and disparities in proton therapy use among patients with head and neck cancer receiving radiotherapy to primary disease sites....
9.
Dunn L, Riaz N, Fury M, McBride S, Michel L, Lee N, et al.
Int J Radiat Oncol Biol Phys
. 2019 Nov;
106(3):564-570.
PMID: 31678634
Purpose: Activation of the PI3K/mTOR signaling pathway is common in head and neck squamous cell carcinoma (HNSCC). BYL719 is an α-specific PI3K inhibitor that is synergistic and efficacious when combined...
10.
Adkins D, Ley J, Michel L, Wildes T, Thorstad W, Gay H, et al.
Oral Oncol
. 2016 Oct;
61:1-7.
PMID: 27688097
Objectives: We previously reported the efficacy of nab-paclitaxel added to cisplatin, 5-FU, and cetuximab (APF-C) followed by concurrent high dose bolus cisplatin and radiation therapy (CRT) in patients with locally...